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Purpose: Investigate the impact of black versus white race, socioeconomic status (SES), and comorbidity burden
on oropharyngeal cancer (OPC) survival.
Materials and methods: This study retrospectively analyzed patients diagnosed between 1991 and 2012 at an
urban tertiary care center with a high volume of head and neck cancer referrals. Data gathered included de
mographics, human papilloma virus (HPV) status, follow-up time, comorbidities, smoking history, and overall
survival. SES was extrapolated from the 2000 and 2010 censuses. Analysis of variance, chi-square tests, multi
variable Cox proportional hazards models, Cox proportional hazards regression, Kaplan Meier curves and the logrank test were utilized.
Results: Of 208 charts reviewed, 192 patients met inclusion criteria. Black patients had significantly (p < 0.001)
poorer survival at 1, 2, and 5 years than white patients (5-year survival: 32% vs 64%); this discrepancy persisted
in only HPV-negative disease (20% vs 50%). In the HPV-negative subgroup, there was no racial difference in
treatment modality received, Charlson Comorbidity Index, and proportion receiving inadequate, noncurative or
no treatment. Univariate analysis identified significant differences in median household income, education level,
and stage at presentation between black and white subgroups. Multivariate analysis identified white race and
HPV-positive status as independent predictors of overall survival, but SES and stage at presentation were not.
Conclusion: SES did not explain the greater survival in HPV-negative white versus black patients. This indicates
that race is an independent predictor of survival; future studies should examine more accurate indicators of SES
and genetic differences in tumors of black and white patients.

1. Introduction

status was made, race was no longer associated with significant survival
difference among patients with OPC [10]. However, the study only
included 81 patients with OPC and was restricted to patients undergoing
surgical treatment.
The current study aimed to determine whether race and SES may
correlate with prognosis in patients with OPC.

While it is well-established that tobacco and alcohol use and negative
human papillomavirus (HPV− ) status are correlated with poorer sur
vival in head and neck cancer [1–3], the impact of socioeconomic status
(SES) and race have yet to be extensively studied in oropharyngeal
cancer (OPC). Decreased survival in OPC has been reported in locations
of lower SES [4–7]. An association between higher SES and positive
human papillomavirus (HPV+) status disease has also been identified
[8,9]. Reduced survival has been reported in black patients, which may
be due to a lower prevalence of HPV+ disease in this population
[10–12]. Indeed, Jiron et al. demonstrated that once adjustment for HPV

2. Materials and methods
This retrospective cohort study was approved by our health system’s
institutional review board (IRB #8715). The health system’s virtual data
warehouse (VDW) tumor registry was queried in September 2017 to
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identify patients with oropharyngeal squamous cell tumors from June
1991 to December 2012 using the International Classification of Disease
for Oncology, Third Edition, codes (C01, C09.0, C09.1, C09.8, C09.9,
C10.0, C10.1, C10.2, C10.3, C10.4, C10.8, and C10.9). Patients with at
least carcinoma in situ were included, and patients with non-squamous
cell tumors were excluded. Chart review was performed in 2018 and
2019 to supplement and verify VDW data.
Patient-specific information included age, sex, race, vital status, date
of death, date of diagnosis, and last date of contact. Disease-specific
information included the HPV status and stage at presentation accord
ing to the American Joint Committee on Cancer, 7th edition (AJCC-7)
criteria [13]. Of note, because the data collected was from patients
diagnosed between June 1991 and December 2012, AJCC-8 staging was
not used.

overall survival after confirming that proportional hazards assumptions
were met using both the inclusion of time-dependent covariates in the
model (all non-significant) and employing a proportionality test in
PROC PHREG. Only patients with all pertinent variable data available
were included in multivariable analysis. Kaplan Meier curves and the
log-rank test evaluated survival. Statistical significance was set at p <
0.05. All analyses were performed using SAS 9.4 (SAS Institute Inc.,
Cary, NC, http://www.sas.com, RRID:SCR_008567).
3. Results
Of 208 patients initially identified for possible inclusion, 16 patients
were excluded (2 patients with “other” race, 3 patients with missing
race, and 11 patients with missing HPV status); this resulted in 192
patients being included in the study. Univariate hazard ratio of death for
black versus white patients revealed statistically significant lower
overall survival for black patients (2.32, 95% CI [1.60, 3.35]). Hazard
ratios of death were then calculated for the HPV-positive (HPV+) and
HPV-negative (HPV− ) subgroups; this demonstrated that in the HPV+
group, there was not a statistically significant increased risk of death in
black patients (1.55, 95% CI [0.80, 2.99]), and in the HPV− group, the
increased risk of death in black patients persisted (2.42, 95% CI [1.49,
3.94]).
Survival probabilities at 1, 2, and 5 years were calculated for the
entire cohort, the HPV+ subgroup, and the HPV− subgroup (Table 1).
Significant differences are seen in survival probabilities between black
and white patients in both the overall cohort and the HPV− subgroup at
1, 2, and 5 years, with black patients having poorer survival probability
at each interval. In the HPV+ subgroup, there was not a significant
difference in survival probability at 1, 2, and 5 years.
As survival discrepancies were identified between black and white
patients in both the overall cohort and the HPV− subgroup, the average
CCIs of these patient groups were examined. There was no significant
difference in average CCI between whites and blacks in either the overall
cohort (2.83 vs 2.56, p = 0.612) and the HPV− subgroup (2.46 vs 2.03, p
= 0.549).
Univariate analysis was then performed to compare black and white
patients in both the overall cohort and the HPV− subgroup (Tables 2 and
3). In the overall cohort, white patients were more likely to have HPV+
disease. Black patients were more likely to present with stage 4 disease,
have shorter follow-up times, and live in census-blocks with lower levels
of education, lower median household income, higher proportion of
residents living under the poverty line, and lower proportion of houses
occupied and owned. There was no significant difference in age at pre
sentation, gender, or smoking history between black and white patients
in the entire cohort.
In the HPV− subgroup, the differences noted in the overall cohort
between black and white patients persisted, with black patients more
likely to present with stage 4 disease, have shorter follow-up times, and
live in census-blocks with lower levels of education, lower median
household income, higher proportion of residents living under the
poverty line, and lower proportion of houses occupied and owned.

2.1. Socioeconomic data
As socioeconomic data at the individual level was not available
within the electronic health record, census-block level data from the
2000 and 2010 US Census, depending on diagnosis date, was used as a
proxy for SES of study patients. Census-block data prior to 2000 was not
accessible. The census/SES data used corresponded to date of diagnosis,
with those occurring prior to 2000 using the 2000 census data and those
during or after 2000 using the 2010 census data. This data was obtained
in April 2019 and included median household income, percentage of
residents who achieved various levels of education, percentage of resi
dents living under the 100% poverty line, and percentage of homes
owned or occupied in the census-block.
2.2. Comorbidities
Comorbidities collected included myocardial infarction, congestive
heart failure, peripheral vascular disease, cardiovascular disease, de
mentia, chronic pulmonary disease, connective tissue disease, peptic
ulcer disease, mild chronic liver disease, diabetes mellitus, diabetes with
end-organ damage, hemiplegia, moderate or severe renal disease, tumor
without metastasis, moderate or severe liver disease, metastatic solid
tumor, and human immunodeficiency virus/acquired immunodefi
ciency syndrome. The mean Charlson Comorbidity Index (CCI) for each
study group was calculated [14,15].
2.3. HPV status
Testing for HPV status was done both prospectively and retrospec
tively within the pathology department. If a patient had OPC of un
known HPV status treated before presenting to our institution for
treatment of a recurrence, the HPV status of the primary tumor was
assumed to be the same as that of the recurrent tumor. Patients with
unknown HPV status were excluded.
2.4. Disease status
Patients who were documented as missing any aspect of recom
mended treatment—such as not completing recommended full course of
radiation therapy or missing dose(s) of chemotherapy—were classified
as having inadequate treatment. Follow-up was measured from the date
of diagnosis to last follow-up date, defined as last date of patient contact
with the health system.

Table 1
Survival probability by race at 1, 2, and 5 years (n = 192).

2.5. Statistical analysis

Group

Interval

White

Black

p-Value

Entire cohort

1 year
2 years
5 years
1 year
2 years
5 years
1 year
2 years
5 years

0.91
0.79
0.64
0.95
0.85
0.72
0.84
0.68
0.50

0.68
0.49
0.32
0.88
0.79
0.54
0.57
0.32
0.20

<0.001

HPV-positive

Univariate two-group tests were carried out using analysis of vari
ance for continuous variables and using chi-square or Fisher’s exact test
as appropriate for categorical variables. Cox proportional hazards
regression was used. In addition, multivariable Cox proportional haz
ards models were used to identify possible independent predictors of

HPV-negative

0.187

<0.001

HPV, human papillomavirus.
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Table 2
Univariate comparison by race in the overall cohort (n = 192).
Covariate

Level

Median age at
diagnosis (Q1, Q3)
Gender
HPV status
AJCC-7 stage at
diagnosis
Current smoker
≥20 pack-year
history
Median follow-up
time in months
(Q1, Q2)
Greatest level of
education, mean
% ± SDa

Male
Female
Negative
Positive
1
2
3
4

Less than high
school
High school/
GED
Some college
Associates
Bachelors

Median household
income, mean $ ±
SDa
% under poverty line,
mean ± SDa
Houses occupied,
mean % ± SDa
Houses owned, % ±
SDa

Postgraduate
degree
Doctorate

White, n =
124 (%)

Black, n =
68 (%)

59.5
(53.85,
65.27)
99 (79.84)
25 (20.16)
44 (35.48)
80 (64.52)
10 (8.13)
13 (10.57)
39 (31.71)
61 (49.59)
25 (23.36)
63 (59.43)

58.85
(53.47,
65.97)
56 (82.35)
12 (17.65)
44 (64.71)
24 (35.29)
8 (11.94)
2 (2.99)
7 (10.45)
50 (74.63)
20 (35.71)
38 (67.86)

64.71
(26.89,
98.07)
11.19 ± 8.3

22.05
(7.67,
63.47)
21.17 ±
10.57
32.28 ±
7.67
25.68 ±
7.14
6.73 ± 5.72
8.17 ± 6.65

29.66 ± 9.5
24.82 ±
6.03
8.31 ± 2.88
16.49 ±
8.94
8.81 ± 6.87

Table 3
Univariate comparisons by race in HPV− subgroup (n = 88).
pValue

Level

0.742

Median age at
diagnosis (Q1, Q3)

0.673

Gender

Male
Female

AJCC-7 stage at
diagnosis

1
2
3
4

<0.001
<0.001

Current smoker
≥20 pack-year history
Median followup time
in months (Q1, Q2)

0.094
0.293
0.002

Greatest level of
education, mean %
± SDa

<0.001
0.157

0.083
<0.001
0.008

0.73 ± 0.82
62,862 ±
24,360

0.67 ± 0.95
31,861 ±
16,765

0.737
<0.001

8.29 ± 9.11

30.74 ±
16.36
76.59 ±
10.4
53.77 ±
17.66

<0.001

Less than high
school
High school/
GED
Some college
Associates
Bachelors

0.530

5.29 ± 5.06

91.96 ±
5.18
80.37 ±
15.39

Covariate

Median household
income, mean $ ±
SDa
% under poverty line,
mean ± SDa
Houses occupied,
mean % ± SDa
Houses owned, % ±
SDa

<0.001
<0.001

Graduate
school
Doctorate

White, n =
44 (%)

Black, n =
44 (%)

61.74
(55.85,
65.27)
29 (65.91)
34.09
(34.09)
6 (13.95)
2 (4.65)
14 (32.56)
21 (48.84)
11 (30.56)
28 (73.68)
49.72
(15.87,
118.69)
13.53 ±
10.75
29.87 ± 8.0

59.42
(53.47,
65.97)
34 (77.27)
10 (22.73)

0.866

7 (16.28)
0 (0)
5 (11.63)
31 (72.09)
18 (52.94)
29 (78.38)
14.41 (5.85,
39.98)

0.041

25.34 ±
6.58
7.7 ± 2.98
15.56 ±
8.24
7.49 ± 5.24

pValue

0.237

0.057
0.634
<0.001

25.1 ±
11.05
34.51 ±
7.34
24.49 ±
8.33
6.95 ± 7.24
5.4 ± 4.29

<0.001

3.04 ± 3.75

0.002

0.045
0.700
0.644
<0.001

0.51 ± 0.49
55,708 ±
17,877

0.5 ± 1.01
24,668 ±
9755

0.952
<0.001

10.96 ±
11.61
90.98 ± 6.9

37.39 ±
15.14
72.68 ±
7.44
46.42 ±
14.6

<0.001

77.36 ±
18.17

<0.001
<0.001

HPV− , human papillomavirus negative; Q, quartile; AJCC-7, American Joint
Committee on Cancer, 7th edition; SD, standard deviation; GED, General Edu
cation Diploma.
a
White n = 24, Black n = 23.

Q, quartile; HPV, human papillomavirus; AJCC-7, American Joint Committee on
Cancer, 7th edition; SD, standard deviation; GED, General Education Diploma.
a
White n = 55 and Black n = 39.

Again, in the HPV− subgroup, no significant difference was seen in age
at presentation, gender, or smoking history.
Multivariate survival models were created for the overall cohort and
the HPV− subgroup, using race, HPV status, and the statistically sig
nificant variables identified by univariate analysis: stage at presentation,
census-block level education level and median household income (Ta
bles 4 and 5). HPV status was identified as an independent predictor of
survival in the overall cohort, as expected. However, race was also
identified as an independent predictor of survival—with black patients
having poorer survival—in both the entire cohort and the HPV− sub
group, while stage at presentation, census-block level education level
and median household income were not significant predictors in these
models.
Of the 43 HPV− black patients with treatment information, 55.8%
received radiotherapy ± chemotherapy, 11.6% received surgical ther
apy alone, 16.3% received surgical therapy with radiotherapy ±
chemotherapy and 16.3% received noncurative or no treatment. Of the
42 HPV− white patients with treatment information, 52.4% received
radiotherapy ± chemotherapy, 19.0% received surgical therapy alone,
16.7% received surgical therapy with radiotherapy ± chemotherapy and
11.9% received noncurative or no treatment. Fisher’s exact test found no
significant difference in the proportion of HPV− black and white pa
tients receiving inadequate, noncurative or no treatment (46.5% vs
34.9%, p = 0.3801). There was no significant difference in the propor
tion of black and white patients receiving each type of treatment mo
dality either (p = 0.7768).

Table 4
Multivariate survival analysis in overall cohort controlling for stage at presen
tation and socioeconomic status (n = 94).
Variable

Response

Adjusted HR (95%
CI)

pValue

Race
HPV status
Median household
income
Less than high school
AJCC-7 stage at
presentation

Black vs. White
Positive vs Negative
Every $10,000
increase
Every 10% increase
2 vs 1
3 vs 1
4 vs 1

2.58 (1.26, 5.28)
0.20 (0.10, 0.41)
1.13 (0.96, 1.33)

0.010
<0.001
0.134

1.14 (0.81,
2.99 (0.52,
1.57 (0.61,
2.30 (0.91,

1.60)
16.74)
4.03)
5.80)

0.445
0.292

HR, Hazard Ratio; CI, confidence interval; HPV, human papillomavirus; AJCC-7,
American Joint Committee on Cancer, 7th edition.

4. Discussion
This retrospective cohort analysis found HPV+ status and white race
to be independent predictors of survival in OPC—specifically in HPV−
OPC—whereas gender, socioeconomic surrogates (census-block level
median household income and education level), and tumor stage at
presentation did not correlate with survival. CCI, representing the co
morbidity burden of the patient, was not significantly different between
the races in either the overall cohort or in the HPV-negative subgroup,
suggesting that the survival difference cannot be attributed to
3
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This study was limited by a small sample size (N = 192), retro
spective design, and a single institution setting. Additionally, censusblock level socioeconomic data does not represent the patient’s SES
directly, and significant variability of SES can exist within a censusblock. However, while not an ideal method to collect information
about socioeconomic status, using census-block level SES proxy has been
previously accepted as a meaningful solution to obtain SES data in
retrospective studies. It is an imperfect tool to infer socioeconomic data,
but it is the best method available in the case of this retrospective study.
Another issue encountered in this study is the lack of an agreed upon
method for handling patients who did not complete their full, recom
mended treatment for various reasons. It is our hope to spur discussion
on how these patients should be categorized in research. While it is not
ideal to group all inadequately treated patients together, it was not
practical to account for the wide spectrum of inadequate treatment—
from a missed radiation session or chemotherapy to no treatment alto
gether, for example—so a hard line had to be drawn between adequate
and inadequate treatment.
The AJCC-7 staging system was used for staging in this study; un
fortunately, there was no practical way to convert AJCC-7 staging for
each patient to AJCC-8 due to the retrospective nature of the study. This
is a limitation of the study, as AJCC-7 staging is known to be a poor
predictor of outcomes for HPV+ disease. In addition, disease-specific
survival was not able to be examined, as cause of death of patients
was largely unknown. Latency from diagnosis to initiation of treatment
was also not collected; future studies would benefit from including these
data in their analyses to help stratify those receiving “inadequate”
treatment.

Table 5
Multivariate survival analysis in the HPV− subgroup controlling for stage at
presentation and socioeconomic status (n = 47).
Variable

Response

Adjusted HR (95%
CI)

pValue

Race
Median household
income
Less than high school
AJCC-7 stage at
presentation

Black vs. White
Every $10,000
increase
Every 10% increase
3 vs 1
4 vs 1

4.97 (1.57, 15.74)
1.18 (0.89, 1.57)

0.006
0.259

1.08 (0.72, 1.62)
2.03 (0.70, 5.91)
2.24 (0.79, 6.30)

0.723
0.305

HPV− , human papillomavirus negative; HR, hazard ratio; CI, confidence inter
val; AJCC-7, American Joint Committee on Cancer, 7th edition.

comorbidity burden. There was also no significant difference between
proportion of black compared to white patients in the HPV-negative
group receiving inadequate, noncurative or no treatment, suggesting
that adequacy of treatment cannot account for the survival difference
either. Interestingly, univariate analysis did identify a significant dif
ference in follow-up time between black and white patients in both the
overall cohort and the HPV-negative group, with black patients having
shorter follow up time. This is presumably related to the lower socio
economic status identified among black patients (suggested by residing
in census-blocks with lower median household income and lower level
of education observed in black patients). However, since multivariate
analysis did not identify surrogates of SES as predictors of survival, one
cannot conclude that this difference in follow-up time contributed to the
survival difference seen, especially considering that the HPV− group did
not demonstrate a significant difference in the proportion of black
compared to white patients that received inadequate, noncurative or no
treatment.
Race as a predictor of survival in head and neck cancer has been
found in prior studies [16–24]. Previous studies have suggested that the
overall survival by race was due to the lower incidence of HPV+ disease
in black patients [10,11]. This is consistent with the current study, as
there was no survival difference between races in the HPV+ subgroup.
However, other studies demonstrated race to be an independent prog
nosticator. Molina et al. examined 20,915 patients with HNC, and found
that race is an independent predictor of survival outcome, despite
including community poverty level and treatment modality in multi
variate analysis [16]. In multivariate Cox regression analysis, Zandberg
et al. also demonstrated that race was a predictor of survival, with black
patients having poorer survival [18]. Further, Megwalu and Ma found
black patients to have worse prognosis on multivariate analysis,
including treatment modality, in a study of 13,434 patients with OPC
[21]. However, none of these studies included HPV status.
Prior research has also found that black patients tend to present at
later stages [20], which was supported by the findings in this study. This
finding could presumably be related to black patients’ SES, with a higher
likelihood to live in areas of lower income and education, which was
also suggested on univariate analysis in this study. Therefore, this pa
tient population may be more limited by insurance, financial, and
transportation constraints than their white counterparts. However,
presentation at a later stage was not identified as a predictor of poorer
survival on multivariate analysis in the current study.
The findings of this study suggest that, although black patients do
tend to reside in areas of lower SES and present at later stages, these
factors do not appear to be associated with poorer survival in HPV−
disease; however, race itself is, with black patients having a higher risk
of mortality than their white counterparts. It is possible that the reason
for this goes beyond SES and comorbidity. Perhaps black patients may
be more susceptible to certain mutations, resulting in worse prognosis in
HPV− OPC. In a previous study, black patients were found to have more
mutations than non-Hispanic whites in EGFR, HRAS, KRAS, and TP53;
and the presence of three or more mutations correlated with poor
prognosis in patients with HNC [25].

5. Conclusion
Despite the aforementioned limitations, this study contributes to
understanding how race and socioeconomic factors are associated with
outcomes in patients with OPC. HPV− status and black race were found
to be independent predictors of poorer survival in both the overall
cohort of OPC patients and patients with HPV− disease, while control
ling for stage at presentation, socioeconomic status surrogates (highest
education level and median household income), comorbidity burden,
smoking status, age at presentation, gender, and proportion of patients
who underwent inadequate treatment. Results of this study cannot rule
out SES as a predictor of survival, however, they suggest that race itself
is a prognosticator of survival, independent of SES. Future studies should
analyze more accurate surrogates for SES and possible biological dif
ferences in tumors between races. Additionally, although SES was not
identified as a predictor of survival, this study does demonstrate that
black patients tend to reside in census-blocks with lower SES, which is
an important consideration when providing care for these patients, as
they may be limited by insurance, transportation, and financial con
straints, as well as health literacy and access to medical care.
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